key: cord-1008810-in69fhw9 authors: Gee, Julianne; Marquez, Paige; Su, John; Calvert, Geoffrey M.; Liu, Ruiling; Myers, Tanya; Nair, Narayan; Martin, Stacey; Clark, Thomas; Markowitz, Lauri; Lindsey, Nicole; Zhang, Bicheng; Licata, Charles; Jazwa, Amelia; Sotir, Mark; Shimabukuro, Tom title: First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 date: 2021-02-26 journal: MMWR Morb Mortal Wkly Rep DOI: 10.15585/mmwr.mm7008e3 sha: 27bea5b1ac80cf47cac4e3f85d18560dc836eab5 doc_id: 1008810 cord_uid: in69fhw9 Two coronavirus disease 2019 (COVID-19) vaccines are currently authorized for use in the United States. The Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020, and for the Moderna COVID-19 vaccine on December 18, 2020; each is administered as a 2-dose series. The Advisory Committee on Immunization Practices issued interim recommendations for Pfizer-BioNTech and Moderna COVID-19 vaccines on December 12, 2020 (1), and December 19, 2020 (2), respectively; initial doses were recommended for health care personnel and long-term care facility (LTCF) residents (3). Safety monitoring for these vaccines has been the most intense and comprehensive in U.S. history, using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system, and v-safe,* an active surveillance system, during the initial implementation phases of the COVID-19 national vaccination program (4). CDC conducted descriptive analyses of safety data from the first month of vaccination (December 14, 2020-January 13, 2021). During this period, 13,794,904 vaccine doses were administered, and VAERS received and processed† 6,994 reports of adverse events after vaccination, including 6,354 (90.8%) that were classified as nonserious and 640 (9.2%) as serious.§ The symptoms most frequently reported to VAERS were headache (22.4%), fatigue (16.5%), and dizziness (16.5%). A total of 113 deaths were reported to VAERS, including 78 (65%) among LTCF residents; available information from death certificates, autopsy reports, medical records, and clinical descriptions from VAERS reports and health care providers did not suggest any causal relationship between COVID-19 vaccination and death. Rare cases of anaphylaxis after receipt of both vaccines were reported (4.5 reported cases per million doses administered). Among persons who received Pfizer-BioNTech vaccine, reactions reported to the v-safe system were more frequent after receipt of the second dose than after the first. The initial postauthorization safety profiles of the two COVID-19 vaccines in current use did not indicate evidence of unexpected serious adverse events. These data provide reassurance and helpful information regarding what health care providers and vaccine recipients might expect after vaccination. * https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html † Processed VAERS reports are those that have been MedDRA-coded, been deduplicated, and undergone quality assurance and quality control. § Based on the Code of Federal Regulations, a serious adverse event is defined as occurring if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization, permanent disability, congenital anomaly, or birth defect. https://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr Among persons who received Pfizer-BioNTech vaccine, reactions reported to the v-safe system were more frequent after receipt of the second dose than after the first. The initial postauthorization safety profiles of the two COVID-19 vaccines in current use did not indicate evidence of unexpected serious adverse events. These data provide reassurance and helpful information regarding what health care providers and vaccine recipients might expect after vaccination. VAERS is an existing national passive surveillance system for adverse events after vaccination that accepts reports from health care providers, vaccine manufacturers, and the public. Reported signs and symptoms are coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology. ¶ Serious adverse events are followed up by the VAERS program to obtain additional information, including medical records, information from health care providers, and, in the case of death, death certificates and autopsy reports (4) . V-safe is a safety monitoring system established by CDC specifically for the COVID-19 vaccination program. V-safe participants voluntarily self-enroll and receive smartphone text messages providing hyperlinks to web surveys.** During the first week after vaccination, enrollees complete daily surveys asking about local injection site and systemic reactions. Enrollees are asked if they missed work, were unable to perform normal daily activities, or received care from a medical professional because of reported symptoms or heath conditions. Enrollees who report seeking medical care are contacted, and a VAERS report is completed if clinically indicated. Persons who do not report their sex as male are asked about pregnancy status at time of vaccination (initial survey) and about a positive pregnancy test result (3-and 6-week surveys); reported pregnancies are followed up through the v-safe pregnancy registry. † † CDC conducted descriptive analyses of data from VAERS and v-safe during December 14, 2020-January 13, 2021, a ¶ A single VAERS report might be assigned more than one MedDRA Preferred Term; not all terms are medically confirmed diagnoses. https://www.meddra. org/how-to-use/basics/hierarchy ** V-safe enrollees receive daily health check-ins via smartphone text messages that link to web-based surveys for the first 7 days after vaccination, then weekly through 6 weeks postvaccination and then at 3, 6, and 12 months. Among the 6,994 VAERS reports received and processed, 6,844 (97.9%) involved persons not residing in LTCFs; among these, 5,533 (80.8%) received the Pfizer-BioNTech vaccine and 1,311 (19.2%) received the Moderna vaccine. Most reports concerned women ( Among residents of LTCFs who received COVID-19 vaccine, 150 (2.1%) reports of adverse events were submitted to VAERS, including 88 (58.7%) after receipt of the Pfizer-BioNTech vaccine and 62 (41.3%) after receipt of the Moderna vaccine. The median vaccine recipient age was 83 years (range = 17-104 years), and 92 (61%) reports concerned women. Among 122 (81.3%) reports of serious adverse events in LTCF residents, 78 (52.0%) deaths have been reported and investigated; 42 (53.8%) occurred in residents in hospice care or with a do-not-resuscitate status. Death certificate data were available for 17 (22.0%) deaths; causes of death included cardiac disease, dementia, pneumonia, and failure to thrive. Nineteen (24.3%) reported deaths are currently awaiting additional records to establish cause of death. Reported deaths occurred 0-20 days after vaccination (median = 2 days). During December 14, 2020-January 13, 2021, v-safe enrolled 1,602,065 vaccine recipients who completed at least one survey; 814,648 (50.8%) received Pfizer-BioNTech, and 787,417 (49.2%) received Moderna vaccines. The median recipient age was 46 years (range = 16-110 years); 1,106,656 (69.1%) were women. There were 10,825 (0.68%) enrollees who reported that they were pregnant at the time of vaccination, and 262 (0.02%) reported a positive pregnancy test result after vaccination. Solicited local and systemic reactions were similar between persons receiving first doses of Pfizer-BioNTech and Moderna vaccines. Injection site pain, fatigue, headache, myalgia, and chills were most frequently reported (Figure) . Enrollees reported more reactions on the day after vaccination than on any other day. For the Pfizer-BioNTech vaccine, reactions were more frequent after the second dose than the first; the reported rate of fever and chills was more than four times higher after the second dose than after the first ( Table 2 ). and involved local and systemic symptoms; transient local and systemic reactions were also frequently reported in v-safe. Reports of anaphylaxis have been observed after administration of both vaccines (5) . The occurrence of anaphylaxis after receipt of COVID-19 vaccines during the analytic period, 4.5 cases per million doses administered, is within the range reported after receipt of inactivated influenza vaccine (1.4 per million), pneumococcal polysaccharide vaccine (2.5 per million), and live attenuated herpes zoster vaccine (9.6 per million); effective treatments for anaphylaxis exist (6) . VAERS received 113 reports of death after COVID-19 vaccinations; two thirds of these deaths occurred among LTCF residents. All-cause mortality is high in LTCF populations because underlying medical conditions are common. Based on expected rates of background mortality, among the approximately 1 million LTCF residents vaccinated in the first month of the U.S. COVID-19 vaccination program, approximately 7,000 coincidental, temporally associated deaths from all causes would be expected during the analytic period (7) . In contrast, VAERS received 78 reports of death after COVID-19 vaccination in LTCF residents, and approximately one half were in residents who were in hospice or who had a do-not-resuscitate status. Reported causes of death in LTCF residents after COVID-19 vaccination are consistent with expected all-cause mortality in this population. Among deaths in persons with available death certificate and autopsy information who were not LTCF residents, causes of death were consistent with background all-cause mortality and did not indicate any unexpected pattern that might suggest a causal relationship with vaccination (8) . Findings from v-safe monitoring for both vaccines indicate substantial reactogenicity. More reactogenicity was reported after the second dose of Pfizer-BioNTech than the first, particularly on the day after vaccination (data on second dose of Moderna vaccine were not available because of later availability and the dosing interval). These findings are similar to those from clinical trials from both manufacturers, in which injection site pain, fatigue, headache, and myalgia were most frequently reported, with a higher frequency after the second dose in comparable age groups (9,10). V-safe's rapid collection of experiences from vaccinated persons provides valuable information that health care providers can use to counsel vaccine recipients about common reactions and what to expect after vaccination.*** V-safe will be able to provide information on vaccination during pregnancy through follow-up in the v-safe pregnancy registry. *** https://www.cdc.gov/vaccines/covid-19/info-by-product/clinicalconsiderations.html The findings in this report are subject to at least three limitations. First, VAERS analyses are based on passive surveillance, and reporting biases are possible, both from underreporting because of lack of awareness or compliance with reporting requirements as well as from stimulated reporting related to increased awareness. Second, LTCF residents might have been undercounted because the search strategy for identifying LTCF residents relied primarily on vaccination facility documentation. Because of challenges in distinguishing LTCF staff members from LTCF residents aged ≤65 years, only serious VAERS reports were reviewed among those aged ≤65 years who were vaccinated in LTCFs. Finally, v-safe is a voluntary self-enrollment program requiring smartphone access, and all vaccination locations might not have offered equal access to v-safe enrollment materials to vaccine recipients; therefore, information from v-safe might not be representative or generalizable. Mass vaccination with highly effective vaccines is critical to controlling the COVID-19 pandemic. Because of the speed of COVID-19 vaccine development and deployment, there have been concerns among the public about the safety of these new vaccines. In response to these concerns, the U.S. government has implemented the most comprehensive vaccine safety monitoring program in its history. Cases of anaphylaxis after receipt of both authorized vaccines have been observed, though rarely; anaphylaxis rates are comparable with those reported after receipt of other vaccines. No unexpected patterns of reactions or other safety concerns have been identified during early monitoring. CDC and FDA will continue to monitor the safety of COVID-19 vaccines to inform vaccination policy and to maintain public confidence. Adverse events that occur after COVID-19 vaccination should be reported to VAERS. Providers are encouraged to What is already known about this topic? Two COVID-19 vaccines have received Emergency Use Authorization for administration in the United States. In preauthorization clinical trials, local and systemic reactions were reported; no serious safety problems were detected. What is added by this report? Monitoring, conducted as part of the U.S. vaccination program, indicates reassuring safety profiles for COVID-19 vaccines. Local and systemic reactions were common; rare reports of anaphylaxis were received. No unusual or unexpected reporting patterns were detected. promote v-safe enrollment and are required under EUA to report to VAERS vaccination administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after COVID-19 vaccination. † † † These initial findings should provide reassurance to health care providers and to vaccine recipients and promote confidence in the safety of COVID-19 vaccines. Corresponding author: Julianne Gee, jgee@cdc.gov. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States The Advisory Committee on Immunization Practices' interim recommendation for use of Moderna COVID-19 vaccine-United States The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine-United States Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) Reports of anaphylaxis of mRNA COVID-19-United States Risk of anaphylaxis after vaccination in children and adults Development and validation of the nursing home minimum data set 3.0 mortality risk score (MRS3) GA: US Department of Health and Human Services, CDC, National Center for Health Statistics Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration